Detalhe da pesquisa
1.
Race-free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment.
Cancer
; 129(6): 920-924, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606692
2.
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Pediatr Blood Cancer
; 70(8): e30405, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37158620
3.
Improving oncology first-in-human and Window of opportunity informed consent forms through participant feedback.
BMC Med Ethics
; 24(1): 12, 2023 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36803249
4.
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 40(5): 1042-1050, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35932388
5.
Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation.
Cancer Invest
; 40(7): 654-662, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770934
6.
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.
Ann Pharmacother
; 56(8): 927-940, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34963325
7.
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Lancet Oncol
; 22(12): 1777-1786, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34780711
8.
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Invest New Drugs
; 39(4): 1057-1071, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624233
9.
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Ann Pharmacother
; 55(7): 921-931, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33070624
10.
International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care.
J Oncol Pharm Pract
; 27(4): 785-801, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34024179
11.
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
Cancer
; 126(3): 575-582, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31648379
12.
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer
; 123(8): 1228-1234, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32704173
13.
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.
Oncologist
; 25(3): e405-e411, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162805
14.
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist
; 25(3): e528-e535, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162807
15.
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.
J Oncol Pharm Pract
; 26(6): 1461-1474, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32567494
16.
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Cancer
; 125(1): 127-134, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30329148
17.
A call to action to advance patient-focused and decentralized clinical trials.
Cancer
; 130(8): 1193-1203, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38193828
18.
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.
J Pharmacol Exp Ther
; 369(2): 291-299, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30872388
19.
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Invest New Drugs
; 37(1): 87-97, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29781056
20.
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Invest New Drugs
; 37(6): 1198-1206, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30725388